Hypoxia-Targeted-Therapy: Mussel-inspired hollow polydopamine nanocarrier containing MoS nanozyme and tirapazamine with anti-angiogenesis property for synergistic tumor therapy.

Photothermal therapy (PTT) using thermal and tumor microenvironment-responsive reagents is promising for cancer treatment. This study demonstrates an effective PTT nanodrug consisting of hollow-structured, thermally sensitive polydopamine nanobowls (HPDA NB), molybdenum sulfide (MoS) nanozyme, and tirapazamine (TPZ; a hypoxia-responsive drug), with a structure of HPDA@TPZ/MoS NBs which is hereafter denoted as HPTZMoS NBs. With the Fenton-like activity, the HPTZMoS NBs in the presence of HO catalyze the formation of hydroxyl radicals, providing chemodynamic therapy (CDT) effect and deactivating glutathione.

Copper-nitrite complexes release nitric oxide and selectively induce oral precancer and cancer cell apoptosis.

Nitric oxide (NO) is a small, short-lived gas molecule that influences various critical functions in living organisms. It involves multiple physiological processes, including cardiovascular function, metabolism, neurotransmission, immunity, and aberrant NO signaling leads to various disorders such as cardiovascular diseases, diabetes, and cancers. In this study, we explored the potential application of copper-nitrite complexes in treating oral precancer and cancer.

Surgical interventions for degenerative cervical disease: Impact on patient quality of life, mental health, pain relief, and spiritual health.

Introduction: Degenerative cervical diseases can severely affect patients' quality of life (QOL), mental health, and physical function. While surgical intervention is a common treatment, its impact on holistic well-being, including spiritual health, has not been thoroughly explored. This study aimed to evaluate the effects of surgery on QOL, pain-related disability, mental health, and spiritual well-being in patients with degenerative cervical diseases.

Sjögren's Syndrome Is Associated With an Increased Risk of Vitiligo.

Objectives: Limited studies reported the correlation between Sjögren's syndrome (SS) and vitiligo. This study explores the association between SS and the risk of developing vitiligo and assesses comorbidity profiles and medication impacts.

Methods: We conducted a retrospective, population-based analysis using data from Taiwan's National Health Insurance Research Database, spanning 2008 to 2019.